RESUMEN
Fibrillin-1 is an elastin-associated glycoprotein that contributes to the long-term fatigue resistance of elastic fibers as well as to the bioavailability of transforming growth factor-beta (TGFß) in arteries. Altered TGFß bioavailability and/or signaling have been implicated in aneurysm development in Marfan syndrome (MFS), a multi-system condition resulting from mutations to the gene that encodes fibrillin-1. We recently showed that the absence of the latent transforming growth factor-beta binding protein-3 (LTBP-3) in fibrillin-1-deficient mice attenuates the fragmentation of elastic fibers and focal dilatations that are characteristic of aortic root aneurysms in MFS mice, at least to 12 weeks of age. Here, we show further that the absence of LTBP-3 in this MFS mouse model improves the circumferential mechanical properties of the thoracic aorta, which appears to be fundamental in preventing or significantly delaying aneurysm development. Yet, a spinal deformity either remains or is exacerbated in the absence of LTBP-3 and seems to adversely affect the axial mechanical properties of the thoracic aorta, thus decreasing overall vascular function despite the absence of aneurysmal dilatation. Importantly, because of the smaller size of mice lacking LTBP-3, allometric scaling facilitates proper interpretation of aortic dimensions and thus the clinical phenotype. While this study demonstrates that LTBP-3/TGFß directly affects the biomechanical function of the thoracic aorta, it highlights that spinal deformities in MFS might indirectly and adversely affect the overall aortic phenotype. There is a need, therefore, to consider together the vascular and skeletal effects in this syndromic disease.
Asunto(s)
Aorta/patología , Aneurisma de la Aorta Torácica/patología , Proteínas de Unión a TGF-beta Latente/deficiencia , Síndrome de Marfan/patología , Médula Espinal/patología , Animales , Aorta/fisiopatología , Aneurisma de la Aorta Torácica/fisiopatología , Fenómenos Biomecánicos , Genotipo , Proteínas de Unión a TGF-beta Latente/metabolismo , Masculino , Ratones Endogámicos C57BL , Fenotipo , Médula Espinal/fisiopatologíaRESUMEN
Novel procedures to grow pure thin metal oxide films are always welcome in view of their wide range of applications including photocatalysis, solar cells, sensors, and more. In this paper we present a unique way to grow pure nanofilms of metal oxides in vacuo at the temperature range 110-170 K. The reactive layer assisted deposition (RLAD) procedure for thin oxide films growth is based on the evaporation of a reactive metal element on top of a condensed layer of amorphous solid water (D2O-ASW). When applied to metals that do not react with the water layer, the process yields metal nanoclusters on the substrate. We observed that metal oxide films are formed if the redox potential is of -1.0 V or less, leading to deuterium molecules ejection to the gas phase (e.g., Ti and Al) while metals such as Zn, Fe, and Ag, with redox potentials more than -1.0 V, transform into nanoclusters, as revealed by SEM studies. We conclude that the redox potential ia a parameter that enables one to predict the nature and outcome of the ASW buffer layer assisted chemistry.
RESUMEN
Marfan syndrome (MFS) is a multi-system connective tissue disorder that results from mutations to the gene that codes the elastin-associated glycoprotein fibrillin-1. Although elastic fibers are compromised throughout the arterial tree, the most severe phenotype manifests in the ascending aorta. By comparing biaxial mechanics of the ascending and descending thoracic aorta in a mouse model of MFS, we show that aneurysmal propensity correlates well with both a marked increase in circumferential material stiffness and an increase in intramural shear stress despite a near maintenance of circumferential stress. This finding is corroborated via a comparison of the present results with previously reported findings for both the carotid artery from the same mouse model of MFS and for the thoracic aorta from another model of elastin-associated glycoprotein deficiency that does not predispose to thoracic aortic aneurysms. We submit that the unique biaxial loading of the ascending thoracic aorta conspires with fibrillin-1 deficiency to render this aortic segment vulnerable to aneurysm and rupture.
Asunto(s)
Aorta Torácica/fisiopatología , Aneurisma de la Aorta Torácica/complicaciones , Aneurisma de la Aorta Torácica/fisiopatología , Síndrome de Marfan/complicaciones , Fenómenos Mecánicos , Animales , Aorta Torácica/metabolismo , Aorta Torácica/patología , Aneurisma de la Aorta Torácica/metabolismo , Aneurisma de la Aorta Torácica/patología , Modelos Animales de Enfermedad , Tejido Elástico/metabolismo , Elastina/metabolismo , Fibrilina-1/metabolismo , Humanos , Masculino , Ratones , Estrés Mecánico , Soporte de PesoRESUMEN
Platelet factor-4 is a protein belonging to the family of ELR-negative CXC chemokines which binds to fibroblast growth factor and inhibits its mitogenic activity. Platelet factor-4 also inhibits tumor growth by mechanisms involving antiangiogenesis. Antiangiogenic activity in vitro has also been shown for the 24-residue C-terminal fragment of the protein, which decreases the affinity between basic fibroblast growth factor and its cell-surface receptor. In this study, the preferential conformation of this fragment in solution has been determined and has been found to be composed of two helical subdomains. In addition, we show that the fragment forms a specific 1:1 complex with acidic and basic fibroblast growth factors and that both subdomains are probably required for inhibition of fibroblast growth factor-driven mitogenesis. Finally, we show that the binding of the fragment alters the structure of the fibroblast growth factors, although some of such alterations do not seem related with the inhibition of mitogenic activity. Since this fragment has recently been shown to inhibit fibroblast growth factor-induced angiogenesis in vivo when injected intraperitoneally, these results are relevant for developing new antiangiogenic treatments.
Asunto(s)
Inhibidores de la Angiogénesis/metabolismo , Factor 1 de Crecimiento de Fibroblastos/metabolismo , Factor 2 de Crecimiento de Fibroblastos/metabolismo , Factor Plaquetario 4/metabolismo , Secuencia de Aminoácidos , Inhibidores de la Angiogénesis/química , Inhibidores de la Angiogénesis/farmacología , Fluorescencia , Humanos , Datos de Secuencia Molecular , Resonancia Magnética Nuclear Biomolecular , Factor Plaquetario 4/química , Factor Plaquetario 4/farmacología , Estructura Secundaria de Proteína , SolucionesRESUMEN
Platelet factor 4 (PF-4) is a CXC-chemokine with strong anti-angiogenic properties. We have shown previously that PF-4 inhibits angiogenesis by associating directly with fibroblast growth factor 2 (FGF-2), inhibiting its dimerization, and blocking FGF-2 binding to endothelial cells. We now have characterized a small peptide domain (PF-447-70) derived from the C-terminus of PF-4, which conserves anti-angiogenic effects of the parent protein. PF-447-70 inhibited internalization of 125I-FGF-2 by endothelial cells in a time-dependent manner. The peptide reduced FGF-2-stimulated cell migration to control levels in wounded monolayers of bovine capillary endothelial cells. PF-447-70 also reduced FGF-2 induced phosphorylation of MAP kinases ERK-1 and ERK-2, which are essential for migration and survival of endothelial cells. In a serum-free ex vivo angiogenesis assay, the peptide blocked microvessel outgrowth by 89%. A single amino acid substitution within PF-447-70 abolished all inhibitory activities. To simulate a real anti-angiogenic treatment situation, we administered PF-447-70 systemically to mice implanted subcutaneously with FGF-2 containing gelatin sponges with the result of sparse, scattered, and immature vessel growth. The small peptide fragment derived from the angio-inhibitory CXC-chemokine PF-4 might be used as a starting point to develop anti-angiogenic designer drugs for angiogenesis-dependent pathologies such as cancer, diabetic retinopathy, and rheumatoid arthritis.
Asunto(s)
Endotelio Vascular/citología , Factor 2 de Crecimiento de Fibroblastos/metabolismo , Neovascularización Fisiológica/efectos de los fármacos , Fragmentos de Péptidos/química , Fragmentos de Péptidos/farmacología , Factor Plaquetario 4/química , Factor Plaquetario 4/farmacología , Secuencia de Aminoácidos , Animales , Aorta , División Celular , Movimiento Celular , Células Cultivadas , Medio de Cultivo Libre de Suero , Técnicas de Cultivo , Endotelio Vascular/efectos de los fármacos , Activación Enzimática , Humanos , Ratones , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Modelos Biológicos , Datos de Secuencia Molecular , Fragmentos de Péptidos/genética , Factor Plaquetario 4/genética , Estructura Terciaria de Proteína , Ratas , Proteínas Tirosina Quinasas Receptoras/metabolismo , Receptor Tipo 2 de Factor de Crecimiento de Fibroblastos , Receptores de Factores de Crecimiento de Fibroblastos/metabolismoRESUMEN
Thirty patients had distal hamstring release with modified Green technique: 21 spastic diplegics, 8 spastic quadriplegics, and 1 spastic hemiplegic. The average age at the time of surgery was 6.9 years. The average follow-up was 2.5 years. Average improvement of 40 degrees in the popliteal angle was noted at follow-up. Twenty-three patients improved their gait pattern. Nine patients improved one level of walking ability. A popliteal angle over 50 degrees was defined as recurrent. On the basis of this criterion, the recurrence rate was 12.5% (7/56 knees). In all recurrent cases, however, the tightness was less severe than preoperatively. Noncompliance on the part of parents was the chief reason for recurrence. Distal hamstring release is an effective procedure in treatment of cerebral palsy patients with flexion deformity.